In short
Clinical trials investigating Imipramine Hydrochloride are studying how it performs in different patient groups and conditions. The trial data include studies in pain, depression, and cancer, with goals such as measuring symptom change, tissue changes, and overall treatment response. These trials also look at who may benefit most and how outcomes compare with placebo or usual care.
Key points
- Clinical trials investigating Imipramine Hydrochloride are looking at several different patient groups, including people with chronic pain, depression, and certain cancers. Most of the studies are Phase 3, with one Phase 2 cancer study. The pain trials measure change in pain using the Numeric Rating Scale, while the depression trials measure symptom change with tools like MADRS and PHQ-9. The cancer trial focuses on tissue changes in the tumor and immune response after treatment. Overall, the trial data show that Imipramine Hydrochloride is being studied as part of broader treatment strategies, often compared with placebo or usual care.
Overview of the trial program
The trial data show that Imipramine Hydrochloride is being studied in several different clinical settings, not just one disease area. These studies are interventional trials, which means researchers are giving a study treatment or comparing treatment strategies to see what happens.
Most of the available trials are Phase 3 studies, and one study is Phase 2. This means the research is mostly focused on testing how well the study plans work in larger groups of patients, while one study is looking at earlier clinical and tissue effects in cancer.
Pain studies
Several trials study chronic pain conditions, including diabetic polyneuropathy, traumatic or post-operative peripheral neuropathy, central neuropathy of any genesis, and chronic back pain. Neuropathy means nerve damage, and chronic pain means pain that lasts a long time.
These pain studies are described as evaluation of AP707 as add-on treatment, and the comparison is made between a verum arm and a placebo arm. The trial data list Imipramine as one of the study drugs used in these pain research programs.
The main pain endpoint is the change in pain level on the Numeric Rating Scale from baseline to treatment week 14, which is the end of the first treatment phase. This gives a simple 0 to 10 pain score so researchers can compare how much pain changed over time.
Depression studies
Two trials focus on depressive illness, including major depressive disorder and depressive disorder. One study looks at a six-week intensified pharmacological treatment compared with treatment as usual after a first treatment failure, while the other studies a pre-emptive pharmacogenetic strategy for antidepressant selection after prior therapy failure.
Pharmacogenetic means using genetic information to help choose a medicine, and the PREDICT trial compares that personalized approach with standard clinical practice. The listed medicines in these depression studies include Imipramine Hydrochloride and several other antidepressants, showing that the trials are testing treatment strategies rather than only one drug.
The main depression outcomes are symptom severity and symptom remission, measured with the MADRS total score and the PHQ-9. In simple terms, these are rating tools that help show whether depression symptoms are improving after treatment starts.
Cancer study
One Phase 2 trial, called HITCLIF, studies cancer that over-expresses Fascin1, including colon cancer stage II-III, rectal cancer, and breast cancer. Over-expressing means the tumor has a higher-than-usual amount of this marker.
This study compares placebo material with TOFRANIL 50 mg tablets, which are listed in the trial data as the Imipramine-containing treatment. The purpose is to see whether treatment changes the histological and molecular signs of epithelial-mesenchymal transition between biopsy and surgery.
Epithelial-mesenchymal transition is a process where cancer cells change in a way that may help them move and invade nearby tissue. The main outcome measures include tumor budding, cytoplasmic pseudofragments, invasion pattern, and immune infiltrate features such as lymphocytes and macrophages.
Main outcomes and endpoints
The pain studies use the Numeric Rating Scale as their primary outcome, focusing on change from baseline to week 14. This endpoint helps show whether pain is getting better, worse, or staying the same during the study period.
The depression studies use symptom severity scores, mainly MADRS and PHQ-9, to measure how well the treatment strategy works after a new antidepressant is started. The cancer study uses tissue-based endpoints, which means the results are read from tumor samples under the microscope and through related laboratory assessment.
Who the studies are for
The target populations are people with specific medical conditions, not healthy volunteers. These include patients with long-lasting nerve pain, chronic back pain, depressive disorders, and selected cancers with Fascin1 over-expression.
One depression trial specifically includes people who had a first-time treatment failure on their first-line treatment, which means the first medicine did not work well enough. The cancer study includes patients from biopsy diagnosis through surgical resection, and the brief summary says the evaluation is done during that treatment window.
Trial phases and status
The pain studies and the depression studies are all listed as Phase 3, and their status is Completed or Authorised. Phase 3 studies are usually larger and are used to compare treatment strategies in real patient groups.
The cancer trial is Phase 2 and is Authorised, with 180 planned participants. This phase is often used to learn more about early effectiveness and biological changes in the tumor.